DAIICHI SANKYO, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 32
- Registration Number
- NCT02076451
- Locations
- 🇺🇸
Sarah Cannon Research Institute / Tennesee Oncology, Nashville, Tennessee, United States
Cancer Venous Thromboembolism (VTE)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1046
- Registration Number
- NCT02073682
Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2199
- Registration Number
- NCT02072434
- Locations
- 🇪🇸
First site in, Madrid, Spain
🇪🇸Third site in, Madrid, Spain
🇩🇪Bad Friedrichshall, Heilbronn, Germany
DS1040b/Aspirin Drug/Drug Interaction Study
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 18
- Registration Number
- NCT02071004
- Locations
- 🇬🇧
Hammersmith Medicines Research Ltd., London, United Kingdom
A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 110
- Registration Number
- NCT02047565
- Locations
- 🇺🇸
Quintiles, Overland Park, Kansas, United States
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 367
- Registration Number
- NCT02039726
- Locations
- 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 40
- Registration Number
- NCT02004678
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 679
- Registration Number
- NCT01973569
Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 48
- Registration Number
- NCT01956305
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 17
- Registration Number
- NCT01957280
© Copyright 2024. All Rights Reserved by MedPath